Coronavirus (Covid-19): Latest updates and information
Skip to main content Skip to navigation

Dr Louise Hiller

Job Title
Associate Professor
Department
WMS - Warwick Clinical Trials Unit
Phone
02476150179
Research Interests

I work predominately on randomised Phase II and III Breast Cancer Clinical Trials, analysing the clinical data from these as well as their Proteomics and Genomics sub-studies. I have previously researched into outcome measures in Obstetrics and Gynaecology, writing a PhD on the Evaluation of the Statistical Validation of Questionnaires for use as Outcome Measures in Clinical Trials.

  • Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter et al (Select to open full list), 2020. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40), pp. 1-190
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Macpherson, Iain, Rea, Daniel, Hughes-Davies, Luke, McAdam, Karen, Hall, Peter, Mansi, Janine, Wheatley, Duncan, Abraham, Jean, Caldas, Carlos, Gasson, Sophie, O'Riordan, Liz, Wilcox, Maggie, Miles, David, Cameron , David, Wardley, Andrew, 2020. Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology
  • Escala-Garcia, Maria, Guo, Qi, Dörk, Thilo, Canisius, Sander, Keeman, Renske, Dennis, Joe, Beesley, Jonathan, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie et al (Select to open full list), 2019. Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 120 (6), pp. 647-657
  • Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis et al (Select to open full list), 2019. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191), pp. 2599-2612
  • Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M., 2018. Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 18
  • Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, Janet A., Hiller, Louise, Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C., 2017. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer : secondary analysis of the ARTemis trial. Annals of Oncology, 28 (8), pp. 1832-1835
  • Guo, Qi, Burgess, Stephen, Turman, Constance, Bolla, Manjeet K., Wang, Qin, Lush, Michael, Abraham, Jean, Aittomäki, Kristiina, Andrulis, Irene L, Apicella, Carmel, Arndt, Volker, Barrdahl, Myrto, Benitez, Javier, Berg, Christine D., Blomqvist, Carl, Bojesen, Stig E, Bonanni, Bernardo, Brand, Judith S, Brenner, Hermann, Broeks, Annegien et al (Select to open full list), 2017. Body mass index and breast cancer survival : a Mendelian randomization analysis. International Journal of Epidemiology, 46 (6), pp. 1814-1822
  • Thomas, Jeremy St John, Provenzano, Elena, Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Gounaris, Ioannis, Abraham, Jean, Hughes-Davies, Luke, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Caldas, Carlos, Bartlett, John M. S., Cameron, David Allan, Hayward, Richard Laurence et al (Select to open full list), 2017. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), pp. 1069-1077
  • Earl, H. M., Hiller, Louise, Dunn, Janet A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial. Annals of Oncology, 28 (8), pp. 1817-1824
  • Earl, Helena M., Hiller, Louise, Howard, Helen C., Dunn, Janet A., Young, Jennie, Bowden, Sarah J., McDermaid, Michelle, Waterhouse, Anna K., Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M., Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W., Caldas, Carlos et al (Select to open full list), 2017. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial. The Lancet Oncology, 18 (6), pp. 755-769
  • Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J. et al (Select to open full list), 2016. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 8 (341)
  • Ali, H. Raza, Dariush, Aliakbar, Provenzano, Elena, Bardwell, Helen, Abraham, Jean E., Iddawela, Mahesh, Vallier, Anne-Laure, Hiller, Louise, Dunn, Janet A., Bowden, Sarah J., Hickish, Tamas, McAdam, Karen, Houston, Stephen, Irwin, Mike J., Pharoah, Paul D. P., Brenton, James D., Walton, Nicholas A., Earl, Helena M., Caldas, Carlos, 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1)
  • Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
  • Thamm, Douglas, Dorling, Leila, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
  • Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet A., Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris, Hiller, Louise, 2016. Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 115 (12), pp. 1462-1470
  • Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos, Earl, Helena M., 2015. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1)
  • Pirie, Ailith, Guo, Qi, Kraft, Peter, Canisius, Sander, Eccles, Diana M, Rahman, Nazneen, Nevanlinna, Heli, Chen, Constance, Khan, Sofia, Tyrer, Jonathan, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Lush, Michael, Dunning, Alison M, Shah, Mitul, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael et al (Select to open full list), 2015. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 17 (1)
  • Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Lush, M., Kar, S., Beesley, J., Dunning, A. M., Shah, M., Czene, K., Darabi, H., Eriksson, M., Lambrechts, D. et al (Select to open full list), 2015. Identification of Novel Genetic Markers of Breast Cancer Survival. JNCI Journal of the National Cancer Institute, 107 (5)
  • Ali, H. R., Glont, S.- E., Blows, F. M., Provenzano, E., Dawson, S.- J., Liu, B., Hiller, Louise, Dunn, Janet A., Poole, C. J., Bowden, S., Earl, H. M., Pharoah, P. D. P., Caldas, C., 2015. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 26 (7)
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A et al (Select to open full list), 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial. The Lancet Oncology, 16 (6), pp. 656-666
  • Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
  • Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
  • Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, 15 (2), pp. 201-212
  • Abraham, J. E., Guo, Q., Dorling, L., Tyrer, J., Ingle, S., Hardy, R., Vallier, A.-L., Hiller, Louise, Burns, R., Jones, L., Bowden, S. J., Dunn, Janet A., Poole, C. J., Caldas, C., Pharoah, P. P. D., Earl, Helena M., 2014. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clinical Cancer Research, 20 (9), pp. 2466-2475
  • Provenzano, E., Vallier, A. -L., Champ, R., Walland, K., Bowden, S. (Sarah), Grier, Anna, Fenwick, Nicola, Abraham, J. (Janet), Iddawela, M., Caldas, C., Hiller, Louise, Dunn, Janet A., Earl, Helena M., 2013. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer, 108 (4), pp. 866-872
  • Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul D., 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A. et al (Select to open full list), 2012. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8), pp. 1257-1267
  • Gounaris, I., Provenzano, E., Vallier, A. L., Hiller, Louise, Iddawela, M., Hilborne, S., Taylor, K. (Kathryn), Britton, Peter, Earl, Helena M., Sinnatamby, R., 2011. Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 127 (2), pp. 459-469
  • Hiller, Louise, Dunn, Janet A., Higgins, Helen B., Ogburn-Storey, Emma, Loi, Shrushma, Vallier, Anne-Laure, Earl, Helena M., 2011. Optimising patient recall of adverse events over prolonged time periods. Trials, Vol.12 (Suppl.1)
  • Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M., Sculpher, Mark J., 2011. The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17), pp. 2517-2530
  • Hannigan, Adèle, Smith, Paul J., Kalna, Gabriela, Lo Nigro, Cristiana, Orange, Clare, O'Brien, Darren I., Shah, Reshma, Syed, Nelofer, Spender, Lindsay C., Herrera, Blanca, Thurlow, Johanna K., Lattanzio, Laura, Monteverde, Martino, Maurer, Meghan E., Buffa, Francesca M., Mann, Jelena, Chu, David C. K., West, Catharine M. L., Patridge, Max, Oien, Karin A. et al (Select to open full list), 2010. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, Vol.120 (No.8), pp. 2842-2857
  • Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M., Poole, Christopher, 2010. Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3), pp. 266-274
  • Nicholson, Linda J., Smith, Paul R., Hiller, Louise, Szlosarek, Peter W., Kimberley, Christopher, Sehouli, Jalid, Koensgen, Dominique, Mustea, Alexander, Schmid, Peter, Crook, Tim, 2009. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. International Journal of Cancer, Vol.125 (No.6), pp. 1454-1463
  • Pepper, Chris, Lin, Thet Thet, Pratt, Guy, Hewamana, Saman, Brennan, Paul, Hiller, Louise, Hills, R., Ward, Rachel, Starczynski, Jane, Austen, Belinda, Hooper, Laura, Stankovic, Tatjana, Fegan, Chris, 2008. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, Vol.112 (No.9), pp. 3807-3817
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A., Poole, Christopher, 2008. NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8), pp. 1226-1231
  • Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M., Poole, Christopher J., 2008. tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4), pp. 597-603
  • Ainsworth, R., Dziedzic, K., Hiller, Louise, Daniels, J., Bruton, A., Broadfield, J., 2007. A prospective double blind placebo-controlled randomized trial of ultrasound in the physiotherapy treatment of shoulder pain. Rheumatology, Vol.46 (No.5), pp. 815-820
  • Hiller, Louise, Bradshaw, H. D., Radley, S. C., Radley, S., 2007. Criterion validity of the BBUSQ-22: a questionnaire assessing bowel and urinary tract symptoms in women. International Urogynecology Journal, Vol.18 (No.10), pp. 1133-1137
  • Smith, Paul, Nicholson, Linda J., Syed, Nelofer, Payne, Annette, Hiller, Louise, Garrone, Ornella, Occelli, Marcella, Gasco, Milena, Crook, Tim, 2007. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clinical Cancer Research, Vol.13 (No.14), pp. 4061-4068
  • Piper, M. K., Raza, K., Nuttall, S. L., Stevens, R., Toescu, V., Heaton, S., Gardner-Medwin, J., Hiller, Louise, Martin, U., Townend, J., Bacon, P. A., Gordon, Caroline, 2007. Impaired endothelial function in systemic lupus erythematosus. Lupus, Vol.16 (No.2), pp. 84-88
  • Tennant, Ruth, Hiller, Louise, Fishwick, Ruth, Platt, Stephen, Joseph, Stephen, Weich, Scott, Parkinson, Jane, Secker, Jenny, Stewart-Brown, Sarah L., 2007. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS) : development and UK validation. Health and Quality of Life Outcomes, Vol.5 (No.63)
  • Donnelly, P., Hiller, Louise, Bathers, S., Bowden, S., Coleman, R., 2007. Questioning specialists' attitudes to breast cancer follow-up in primary care. Annals of Oncology, 18 (9), pp. 1467-1476
  • Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C. F., Twelves, Chris, 2006. Epirubicin and cyclophosphamide, methotrexate,and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18), pp. 1851-1862
  • Bradshaw, H. D., Hiller, Louise, Farkas, A. G., Radley, S., Radley, S. C., 2006. Development and psychometric testing of a symptom index for pelvic organ prolapse. Journal of Obstetrics and Gynaecology Research, 26 (3), pp. 241-252
  • Pemberton, N. C., Paneesha, S., Hiller, Louise, Starczynski, J., Hooper, L., Pepper, C., Pratt, G., Fegan, C., 2006. The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leukemia & Lymphoma, 47 (7), pp. 1239-1244
  • Sullivan, Alexandra, Syed, Nelofer, Gasco, Milena, Bergamaschi, Daniele, Trigiante, Giuseppe, Attard, Marlene, Hiller, Louise, Farrell, Paul J, Smith, Paul, Lu, Xin, Crook, Tim, 2004. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene, 23 (19), pp. 3328-3337
  • Hussain, S. A., Palmer, D. H., Ganesan, R., Hiller, Louise, Gregory, J., Murray, P. G., Pastorek, J., Young, L., James, N. D., 2004. Carbonic anhydrase IX, a marker of hypoxia : correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncology Reports, 11 (5), pp. 1005-1010
  • Wilson, D., Hiller, Louise, Gray, L., Grainger, M., Stirling, A., James, N., 2003. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clinical Oncology, 15 (7), pp. 400-407
  • Hussain, S. A., Ganesan, R., Hiller, Louise, Murray, P. G., El-Magraby, M. M., Young, L., James, N. D., 2003. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. British Journal of Cancer, 88 (4), pp. 586-592
  • Hiller, Louise, Bradshaw, H. D., Radley, S. C., Radley, S., 2003. A scoring system for the assessment of bowel and lower urinary tract symptoms in women. BJOG: An International Journal of Obstetrics and Gynaecology, 109 (4), pp. 424-430
  • Hussain, S. A., Ganesan, R., Hiller, Louise, Cooke, P. W., Murray, P., Young, L. S., James, N. D., 2003. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncology Reports, 10 (3), pp. 571-576
  • Bergamaschi, Daniele, Gasco, Milena, Hiller, Louise, Sullivan, Alexandra, Syed, Nelofer, Trigiante, Giuseppe, Yulug, Isik, Merlano, Marco, Numico, Gianmauro, Comino, Alberto, Attard, Marlene, Reelfs, Olivier, Gusterson, Barry, Bell, Alexandra K., Heath, Victoria, Tavassoli, Mahvash, Farrell, Paul J, Smith, Paul, Lu, Xin, Crook, Tim, 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3 (4), pp. 387-402
  • Hiller, Louise, Radley, S., Mann, C. H., Radley, S. C., Begum, G., Pretlove, S .J., Salaman, J. H., 2002. Development and validation of a questionnaire for the assessment of bowel and lower urinary tract symptoms in women. BJOG: An International Journal of Obstetrics and Gynaecology, 109 (4), pp. 413-423
  • Batta, Kapila, Goodyear, Helen M., Moss, Celia, Williams, Hywel C., Hiller, Louise, Waters, Ruth, 2002. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas : results of a 1-year analysis. The Lancet, 360 (9332), pp. 521-527
  • Eggar, Richard, Spencer, Amanda, Anderson, David, Hiller, Louise, 2002. Views of elderly patients on cardiopulmonary resuscitation before and after treatment for depression. International Journal of Geriatric Psychiatry, 17 (2), pp. 170-174
  • Gasco, M., Bell, A. K., Heath, V., Sullivan, A., Smith, P., Hiller, Louise, Yulug, I., Numico, G., Merlano, M., Farrell, P. J., Tavassoli, M., Gusterson, B., Crook, T., 2002. Epigenetic inactivation of 14-3-3 s in oral carcinoma : association with p16INK4a silencing and human papillomavirus negativity. Cancer Research, 62 (7), pp. 2072-2076
  • Demain, Sara, Smith, Jan Fereday, Hiller, Louise, Dziedzic, Krysia, 2001. Comparison of group and individual physiotherapy for female urinary incontinence in primary care. Physiotherapy, 87 (5), pp. 235-242
  • Brooks, L. A., Tidy, J. A., Gusterson, B., Hiller, Louise, O'Nions, J., Gasco, M., Marin, M. C., Farrell, P. J., Kaelin, Jr., Crook, T., 2000. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Research, 60 (24), pp. 6875-6877
  • Darnton, S. J., Zgainski, B., Grenier, I., Allister, K., Hiller, Louise, McManus, K. G., Steyn, R. S., 1999. The use of an anabolic steroid (nandrolone decanoate) to improve nutritional status after esophageal resection for carcinoma. Diseases of the Esophagus, 12 (4), pp. 283-288
  • Nicholl, D. J., Bennett, P., Hiller, Louise, Bonifati, V., Vanacore, N., Fabbrini, G., Marconi, R., Colosimo, C., Lamberti, P., Stocchi, F., Bonuccelli, U., Vieregge, P., Ramsden, D. B., Meco, G., Williams, A. C., 1999. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology, 53 (7), pp. 1415-1421
  • Etherington, I. J., Luesley, D. M., Shafi, M. I., Dunn, Janet A., Hiller, Louise, Jordan, J. A., 1997. Observer variability among colposcopists from the West Midlands region. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (12), pp. 1380-1384
Title Funder Award start Award end
NIHR PGfAR via Newcastle: Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) National Institute for Health Research (DoH) 18 May 2020 17 May 2026
NIHR Programme Grant:Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) Year 6 costs National Institute for Health Research (DoH) 03 Feb 2020 02 Feb 2026
NIHR HTA Stage 2: Volatile vs Total intravenous Anaesthesia for major non-cardiac surgery ? a randomised controlled triaL (VITAL) National Institute for Health Research (NIHR DoH) 01 Nov 2020 30 Apr 2025
ALIFE 2 extension 2 - link to 61060 National Institute for Health Research (DoH) 01 Mar 2020 28 Feb 2022
ALIFE 2 extension 2 - link to 61060 University Hospitals Coventry and Warwickshire NHS Trust 01 Mar 2020 28 Feb 2022
ALIFE 2 extension 2 - link to 61060 Amsterdam Universitair Medische Centra 01 Mar 2020 28 Feb 2022
NIHR HTA: Whole slide imaging in pathology National Institute for Health Research (DoH) 01 Nov 2018 31 Oct 2021
ALIFE2-EXTENSION National Institute for Health Research (DoH) 01 May 2018 29 Feb 2020
Persephone extension and supplement National Institute for Health Research (DoH) 01 Jul 2016 30 Jun 2019
ARTemis: Avastin randomised trial with nEo-adjuvant cheMotherapy for patinets with early breat cancer : Analysis Extension Cambridge University Hospitals NHS Foundation Trust 01 Jul 2011 31 Dec 2018
ARTEMIS Pre-operative Avastin with neo-adjuvant chemotherapy Years 7,8 & 9 Support Funding Cancer Research UK 01 May 2015 30 Apr 2018
Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER 2 negative breast cancer Artemis Year 9 Funding - staff - Late Phase Study Cancer Research UK 01 May 2017 30 Apr 2018
Second Recosting for extension of the Persephone HTA Trial National Institute for Health Research (DoH) 01 Jul 2013 30 Jun 2016
HTA FULL proposal: OPTIMA (Pilot Study) National Institute for Health Research (DoH) 01 Sep 2012 31 Aug 2013
3 month extention of the Persephone HTA Trial National Institute for Health Research (DoH) 01 Apr 2013 30 Jun 2013
Molecular profiling of post menopausal women with breast cancer on neoadjuvant exemestane or tamoxifen (MONET) University of Cambridge 01 Apr 2007 31 Mar 2009
Warwick Edinburgh Mental Wellbeing Scale: Proposal for Validation of the Scale on Data Collected in the HEBS Population Survey in September 2006 NHS Health Scotland 01 Jan 2007 30 May 2007